Treatment
S-1 clinical trials
We’re tracking 792 recruiting studies that include S-1, each written for real people, not researchers, below.
Recruiting studies
- NCT06437522RecruitingPhase 2
New drug combo for recurrent head and neck cancer
This trial tests a new drug combination (BL-B01D1 plus a PD-1 inhibitor) for people with advanced head and neck cancer or other solid tumors that have come back or spread. It aims to see if the treatment can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06437509RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for extensive-stage small cell lung cancer
This trial tests a new drug combination—BL-B01D1 plus a PD-1 immunotherapy—for people who have just been diagnosed with extensive-stage small cell lung cancer and have not had any prior treatment for it. The goal is to see if this combination can help shrink or control the cancer better than standard therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06405425RecruitingPhase 2
Study of BL-B01D1 and immunotherapy for advanced bladder cancer
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05329532RecruitingPhase 1/Phase 2
Modi-1 cancer vaccine for several hard-to-treat cancers
This Phase 1/2 study tests a cancer vaccine called Modi-1 Moditope in people with advanced triple-negative breast cancer, head and neck cancer, ovarian/high-grade serous cancer, or kidney cancer. It aims to help the immune system better recognize and attack the cancer.
Brighton, DefaultAges 18 years+ - NCT06364384RecruitingPhase 2
Chemo, radiation, and immunotherapy for rectal squamous cell carcinoma
This trial tests a combination of chemotherapy (cisplatin and 5-FU), radiation, and an immunotherapy drug (PD-1 antibody) for people with a rare type of rectal cancer that hasn't spread. The goal is to see if this treatment can shrink or eliminate the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06281405RecruitingPhase 2
CAPOX and immunotherapy with or without radiation for rectal cancer
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
ShanghaiAges 18–70 - NCT06008054RecruitingPhase 2
New drug combo for advanced gastrointestinal cancers
This trial tests two new drugs (BL-B01D1 and SI-B003) alone or with a standard immunotherapy for advanced gastrointestinal cancers. The goal is to see if these combinations shrink tumors and are safe.
Beijing, Beijing MunicipalityAges 18–75 - NCT06203132RecruitingPhase 3
Doravirine vs Dolutegravir for first-time HIV treatment
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
Nova Iguaçu, Rio de JaneiroAges 18 years+ - NCT06190275Recruiting
Immune cell therapy for advanced head and neck cancer
This trial tests a new immune cell therapy (GT201) combined with a PD-1 inhibitor for advanced head and neck cancer. It aims to see if your own immune cells, collected from your tumor, can be boosted to fight the cancer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06144671RecruitingPhase 1/Phase 2
Custom immune cell therapy for advanced solid tumors
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06132477RecruitingPhase 4
Study of GLP-1 medicines after weight loss surgery
This study looks at what happens when people taking a GLP-1 medication (like Ozempic) either stop or continue it after weight loss surgery. The goal is to learn whether staying on the medicine helps with long-term weight control.
Columbia, MissouriAges 18 years+ - NCT06084364RecruitingPhase 4
Steroid vs saline injection vs occupational therapy for thumb arthritis
This study compares a steroid injection (Kenacort), a saltwater (saline) injection, and occupational therapy to see which works best for thumb base osteoarthritis pain. It may help you if you have thumb pain with swelling and want to avoid surgery.
BodøAges 40–85 - NCT06069622Recruiting
How a gene affects weight-loss treatment response
This study looks at how a weight-loss medication affects people with obesity who may have a specific gene difference (caveolin-1). It aims to understand why some people respond differently to GLP-1 treatments like semaglutide.
Boston, MassachusettsAges 18 years+ - NCT06038461RecruitingPhase 1/Phase 2
Surufatinib with chemo for advanced neuroendocrine tumors
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT05660980RecruitingPhase 1/Phase 2
Oral and monthly shots for HIV control in children
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
Atlanta, GeorgiaAges 2–11 - NCT05664009Recruiting
Testing Redsenol-1 Plus for cancer-related fatigue
This trial tests a natural supplement for fatigue in cancer survivors. You must have had fatigue for at least a month and be otherwise stable.
London, OntarioAges 18 years+ - NCT05654922RecruitingPhase 3
Prevent lung transplant airways scarring with ARINA-1
This Phase 3 trial tests ARINA-1 to slow or prevent worsening lung transplant scarring in the breathing tubes (bronchiolitis obliterans). It may help people who are showing early decline in lung function but are not yet at advanced disease.
Phoenix, ArizonaAges 18–75 - NCT05562830RecruitingPhase 1/Phase 2
Study for bladder or urinary tract cancer after PD-1 failure
This Phase 1/2 study tests investigational cancer treatment(s) in people with locally advanced or metastatic urothelial cancer that has not responded to PD-1/PD-L1 immunotherapy. It may help by trying a new approach after prior checkpoint treatment has stopped working or the cancer returns.
Orange, CaliforniaAges 18 years+ - NCT05492682RecruitingPhase 1
First-in-human treatment for cancer using a drug injected into tumors
This Phase 1 trial tests PeptiCRAd-1, a treatment injected into a tumor, to see how safe it is and whether it can shrink cancers. It studies people whose cancer has come back or can’t be treated with standard options.
FrankfurtAges 18 years+ - NCT05356104RecruitingPhase 2
GLP-1 treatment to slow small blood-vessel brain damage
This Phase 2 study tests whether a GLP-1–like medicine can slow worsening “small vessel” disease changes in the brain and related walking and thinking problems. It aims to see if the treatment can prevent progression in people who already show early brain changes on MRI.
Wenzhou, ZhejiangAges 55–80 - NCT05143307Enrolling by invitationPhase 1
Follow-up study for adults who received EBT-101 for HIV
This study checks how adults are doing long-term after receiving an HIV treatment called EBT-101 in an earlier study. It helps researchers understand safety and longer-term effects over time.
San Francisco, CaliforniaAges 18 years+ - NCT05184803RecruitingPhase 2
Pre-surgery chemo for advanced stomach cancer with lymph spread
This Phase 2 study tests a combination chemotherapy regimen given before surgery for stomach cancer that cannot be fully removed (unresectable), including spread to lymph nodes. The goal is to shrink the cancer and improve control with a well-known set of medicines given in a specific order.
Seoul, SeoulAges 19 years+ - NCT05103683RecruitingPhase 1
First-time test of TORL-1-23 for advanced solid tumors
This early study tests a new drug (TORL-1-23) in people with advanced solid cancers. It aims to find the safest dose and see how the tumor responds.
Fullerton, CaliforniaAges 18 years+ - NCT04875078Enrolling by invitation
UVA-1 light treatment for hand skin tightness in scleroderma
This study tests whether UVA-1 light sessions can loosen tight skin and improve hand function in people with scleroderma. If you qualify, you would attend UVA-1 treatments twice a week for the study period.
Murray, UtahAges 18 years+
Common questions
- Are there clinical trials studying S-1?
- Yes. Clin2 currently lists 792 recruiting studies that include S-1, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a S-1 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is S-1 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether S-1 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.